These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
262 related articles for article (PubMed ID: 20515975)
1. Antiangiogenic cancer therapy: monitoring with molecular US and a clinically translatable contrast agent (BR55). Pysz MA; Foygel K; Rosenberg J; Gambhir SS; Schneider M; Willmann JK Radiology; 2010 Aug; 256(2):519-27. PubMed ID: 20515975 [TBL] [Abstract][Full Text] [Related]
2. Dual-targeted contrast agent for US assessment of tumor angiogenesis in vivo. Willmann JK; Lutz AM; Paulmurugan R; Patel MR; Chu P; Rosenberg J; Gambhir SS Radiology; 2008 Sep; 248(3):936-44. PubMed ID: 18710985 [TBL] [Abstract][Full Text] [Related]
3. Squamous Cell Carcinoma Xenografts: Use of VEGFR2-targeted Microbubbles for Combined Functional and Molecular US to Monitor Antiangiogenic Therapy Effects. Baetke SC; Rix A; Tranquart F; Schneider R; Lammers T; Kiessling F; Lederle W Radiology; 2016 Feb; 278(2):430-40. PubMed ID: 26313618 [TBL] [Abstract][Full Text] [Related]
4. Tumor angiogenic marker expression levels during tumor growth: longitudinal assessment with molecularly targeted microbubbles and US imaging. Deshpande N; Ren Y; Foygel K; Rosenberg J; Willmann JK Radiology; 2011 Mar; 258(3):804-11. PubMed ID: 21339349 [TBL] [Abstract][Full Text] [Related]
5. Intra-Animal Comparison between Three-dimensional Molecularly Targeted US and Three-dimensional Dynamic Contrast-enhanced US for Early Antiangiogenic Treatment Assessment in Colon Cancer. Wang H; Lutz AM; Hristov D; Tian L; Willmann JK Radiology; 2017 Feb; 282(2):443-452. PubMed ID: 27490690 [TBL] [Abstract][Full Text] [Related]
6. US imaging of tumor angiogenesis with microbubbles targeted to vascular endothelial growth factor receptor type 2 in mice. Willmann JK; Paulmurugan R; Chen K; Gheysens O; Rodriguez-Porcel M; Lutz AM; Chen IY; Chen X; Gambhir SS Radiology; 2008 Feb; 246(2):508-18. PubMed ID: 18180339 [TBL] [Abstract][Full Text] [Related]
7. BR55: a lipopeptide-based VEGFR2-targeted ultrasound contrast agent for molecular imaging of angiogenesis. Pochon S; Tardy I; Bussat P; Bettinger T; Brochot J; von Wronski M; Passantino L; Schneider M Invest Radiol; 2010 Feb; 45(2):89-95. PubMed ID: 20027118 [TBL] [Abstract][Full Text] [Related]
8. Three-dimensional ultrasound molecular imaging of angiogenesis in colon cancer using a clinical matrix array ultrasound transducer. Wang H; Kaneko OF; Tian L; Hristov D; Willmann JK Invest Radiol; 2015 May; 50(5):322-9. PubMed ID: 25575176 [TBL] [Abstract][Full Text] [Related]
9. VEGFR2-Targeted Contrast-Enhanced Ultrasound to Distinguish between Two Anti-Angiogenic Treatments. Payen T; Dizeux A; Baldini C; Le Guillou-Buffello D; Lamuraglia M; Comperat E; Lucidarme O; Bridal SL Ultrasound Med Biol; 2015 Aug; 41(8):2202-11. PubMed ID: 25980323 [TBL] [Abstract][Full Text] [Related]
11. Quantification and monitoring of inflammation in murine inflammatory bowel disease with targeted contrast-enhanced US. Deshpande N; Lutz AM; Ren Y; Foygel K; Tian L; Schneider M; Pai R; Pasricha PJ; Willmann JK Radiology; 2012 Jan; 262(1):172-80. PubMed ID: 22056689 [TBL] [Abstract][Full Text] [Related]
12. Three-dimensional Dynamic Contrast-enhanced US Imaging for Early Antiangiogenic Treatment Assessment in a Mouse Colon Cancer Model. Wang H; Hristov D; Qin J; Tian L; Willmann JK Radiology; 2015 Nov; 277(2):424-34. PubMed ID: 26020439 [TBL] [Abstract][Full Text] [Related]
13. Ultrasound Molecular Imaging of Angiogenesis Using Vascular Endothelial Growth Factor-Conjugated Microbubbles. Wang J; Qin B; Chen X; Wagner WR; Villanueva FS Mol Pharm; 2017 Mar; 14(3):781-790. PubMed ID: 28165246 [TBL] [Abstract][Full Text] [Related]
15. Ultrasound Molecular Imaging With BR55, a Predictive Tool of Antiangiogenic Treatment Efficacy in a Chemo-Induced Mammary Tumor Model. Helbert A; Von Wronski M; Colevret D; Botteron C; Padilla F; Bettinger T; Tardy I; Hyvelin JM Invest Radiol; 2020 Oct; 55(10):657-665. PubMed ID: 32229739 [TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic Modeling of Targeted Ultrasound Contrast Agents for Quantitative Assessment of Anti-Angiogenic Therapy: a Longitudinal Case-Control Study in Colon Cancer. Turco S; El Kaffas A; Zhou J; Lutz AM; Wijkstra H; Willmann JK; Mischi M Mol Imaging Biol; 2019 Aug; 21(4):633-643. PubMed ID: 30225758 [TBL] [Abstract][Full Text] [Related]
17. Ultrasound Molecular Imaging of the Breast Cancer Neovasculature using Engineered Fibronectin Scaffold Ligands: A Novel Class of Targeted Contrast Ultrasound Agent. Abou-Elkacem L; Wilson KE; Johnson SM; Chowdhury SM; Bachawal S; Hackel BJ; Tian L; Willmann JK Theranostics; 2016; 6(11):1740-52. PubMed ID: 27570547 [TBL] [Abstract][Full Text] [Related]
18. VEGFR2-Targeted Three-Dimensional Ultrasound Imaging Can Predict Responses to Antiangiogenic Therapy in Preclinical Models of Colon Cancer. Zhou J; Wang H; Zhang H; Lutz AM; Tian L; Hristov D; Willmann JK Cancer Res; 2016 Jul; 76(14):4081-9. PubMed ID: 27206846 [TBL] [Abstract][Full Text] [Related]
19. Liver dysplasia: US molecular imaging with targeted contrast agent enables early assessment. Grouls C; Hatting M; Rix A; Pochon S; Lederle W; Tardy I; Kuhl CK; Trautwein C; Kiessling F; Palmowski M Radiology; 2013 May; 267(2):487-95. PubMed ID: 23360735 [TBL] [Abstract][Full Text] [Related]